Smoking high-potency marijuana every day could increase the chances of developing psychosis by nearly five times, according to the biggest-ever study to examine the impact of pot on psychotic disorder rates.
Psychotic disorders — in which people lose touch with reality — are typically triggered by factors including genetics and the environment. But experts say the new study’s findings have implications for jurisdictions legalizing marijuana, warning they should consider the potential impact on their mental health services.
“If we think there’s something particular about (high-potency), then making that harder to get a hold of, could be a useful harm-reduction measure,” said Suzanne Gage, of the University of Liverpool, who was not connected to the new study.
Researchers at King’s College London and elsewhere analyzed data from a dozen sites across Europe and Brazil from 2010 to 2015. About 900 people who were diagnosed with a first episode of the disorder at a mental health clinic, including those with delusions and hallucinations, were compared with more than 1,200 healthy patients. After surveying the patients about their use of cannabis and other drugs, researchers found daily marijuana use was more common among patients with a first episode of psychosis compared with the healthy, control group.
The scientists estimated that people who smoked marijuana on a daily basis were three times more likely to be diagnosed with psychosis compared with people who never used the drug. For those who used high-potency marijuana daily, the risk jumped to nearly five times. The paper was published online Tuesday by the journal Lancet. It was paid for by funders including Britain’s Medical Research Council, the Sao Paulo Research Foundation and the Wellcome Trust.
“If you decide to use high-potency marijuana, you should bear in mind: Psychosis is a potential risk,” said Dr. Marta Di Forti, of King’s College London and the study’s lead author. She said it was unknown how frequently people could smoke lower-potency marijuana without raising their likelihood of psychosis, but that less than weekly use appeared to pose no risk.
Di Forti and colleagues estimated that in Amsterdam, about half of new psychosis cases were associated with smoking high-potency pot.
Gage noted that it was possible that people with a family history of psychosis or other risk factors might be more susceptible to developing problems like psychosis or schizophrenia if they used cannabis.
“That could be the thing that tips the scale for some people,” she said. “Cannabis for them could be an extra risk factor, but it definitely doesn’t have to be involved. If you use cannabis, it doesn’t mean you are definitely going to develop psychosis.”
It’s also possible that the people who experience psychotic episodes may be more likely to use marijuana, Gage points out in an accompanying editorial to the study. “Di Forti and colleagues’ study asks participants about their cannabis use prior to their first episode psychosis diagnosis, but it is possible that subclinical symptoms might have existed prior to cannabis initiation, meaning that associations in the opposite direction cannot be ruled out,” she writes.
More research is needed, she said, both to establish a causal relationship and to figure out who may be most susceptible to the health risks of marijuana.
“Given the changing legal status of cannabis across the world, and the associated potential for an increase in use, the next priority is to identify which individuals are at risk from daily potent cannabis use, and to develop educational strategies and interventions to mitigate this,” Gage writes.